Definium Therapeutics to release Phase 3 anxiety drug study results
Tweet Send to a Friend
Definium Therapeutics, Inc. (Nasdaq: DFTX) announced it will host a webcast on September 14, 2026, to discuss topline results from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


